ONCOLYTICS BIOTECH INC 8-K — AI Bull & Bear Analysis

The 8-K filing confirms that Oncolytics Biotech is leveraging the ASCO platform to share mechanistic data on pelareorep, creating a tension between scientific validation and financial reality. While the translational data provides a theoretical bridge to commercial viability through combination partnerships, the market must weigh this against the lack of a clear path to a pivotal trial. The overall impact of the filing is a shift in the narrative toward a science-backed platform, though the stock's trajectory remains tethered to the company's ability to convert these biological signals into regulatory milestones without excessive dilution.